ATENȚIE! Medicamentele pentru slăbit de tip Ozempic, asociate cu un risc crescut de orbire bruscă și incurabilă, avertizează FDA

The FDA has mandated that GLP-1 medications, including Ozempic and Wegovy, carry a warning about a rare eye condition called NAION, which can lead to sudden blindness. This decision follows studies indicating an increased risk of NAION among users of these drugs. NAION affects the optic nerve and can result in irreversible vision loss. The FDA's investigation revealed reports of NAION cases linked to all current GLP-1 medications, although a specific mechanism for this risk remains unidentified. Both Novo Nordisk and Eli Lilly, the manufacturers, emphasize patient safety as a priority.